Canaan has put together an $800 million investment fund. The fund positions Canaan to place a fresh round of bets on early-stage biotechs, continuing the strategy that has delivered it paydays as companies including Johnson & Johnson and Teva have snapped up pieces of its portfolio.
The University System of Maryland (USM) has named business innovator David W. Wise, MALD, as director of the Maryland Momentum Fund (MMF), a $25 million fund to support startups formed within the system’s 12 institutions and its incubators. He joined USM on July 24.
Global University Venturing’s last issue before the summer provides an opportunity to look back at the first six months of the year – as the data reveals, it has been a busy period with activity picking up significantly towards the end of the second quarter.
That increased activity, however, appears not to have translated into a boost for the total amount of capital raised compared with the same period last year. Although there were 44 deals in June, they amounted to only $365.3m of transaction value – a drop of nearly $90m from May.
The University of Maryland, Baltimore (UMB) has been selected as one of “The Great Colleges to Work For” by The Chronicle of Higher Education. The results of its national survey, which were released in the magazine’s Academic Workplace supplement that came out July 21, lauded UMB in the categories of collaborative governance, compensation and benefits, and confidence in senior leadership.
The global population will increase to almost ten billion by 2050 while greenhouse gas emissions from agriculture continue to rise. We need to intensify food production while shrinking agriculture’s impact on the environment. Canadian biotechnology is helping farmers produce more food while simultaneously reducing the environmental footprint of agriculture.
Australian biotech, Trimph, has successfully completed a first-in-human trial of its proprietary bone “glue”, TrimphDent, the only bone graft substitute in the world to be applied in liquid form, halving the time of patient recovery, and requiring no specialised preparation or additional surgical expertise.
This breakthrough will allow Trimph to progress towards registering TrimphDent and launching into global markets, which could provide significantly more affordable and accessible oral surgeries to rural and disadvantaged communities across the globe.
We’re taking all opportunities as we grow to gather user feedback and improve the emocha experience for patients and providers. That’s why earlier this month, our team visited the Puerto Rico Department of Health to learn how our technology has impacted their TB program.
In late 2016, the island was dealing with a TB outbreak in a facility for mentally impaired men. We volunteered the emocha platform pro bono to help manage the outbreak with Dr. Dana Thomas, then Medical Director, championing the effort on behalf of the TB program. Within months, all patients using emocha showed clinical signs of improvement.
“emocha is so important because we have lost staff and fiscal resources over the years,” said Dr. Olga Joglar, TB Control Program Director.
| READ MORE FROM THE NIH |
The emocha platform is used worldwide for TB, HCV, HIV and opioid use disorder treatment. Ready to learn more? Visit our website or reach out at info@emocha.com
